Display options
Cite
Monga S, Weizman A, Gavish M. The Efficacy of the Novel TSPO Ligands 2-Cl-MGV-1 and 2,4-Di-Cl-MGV-1 Compared to the Classical TSPO Ligand PK 11195 to Counteract the Release of Chemokines from LPS-Stimulated BV-2 Microglial Cells. Biology (Basel). 2020;9(9)doi: 10.3390/biology9090291.
Monga, S., Weizman, A., & Gavish, M. (2020). The Efficacy of the Novel TSPO Ligands 2-Cl-MGV-1 and 2,4-Di-Cl-MGV-1 Compared to the Classical TSPO Ligand PK 11195 to Counteract the Release of Chemokines from LPS-Stimulated BV-2 Microglial Cells. Biology, 9(9), . https://doi.org/10.3390/biology9090291
Monga, Sheelu, et al. "The Efficacy of the Novel TSPO Ligands 2-Cl-MGV-1 and 2,4-Di-Cl-MGV-1 Compared to the Classical TSPO Ligand PK 11195 to Counteract the Release of Chemokines from LPS-Stimulated BV-2 Microglial Cells." Biology vol. 9,9 (2020). doi: https://doi.org/10.3390/biology9090291
Monga S, Weizman A, Gavish M. The Efficacy of the Novel TSPO Ligands 2-Cl-MGV-1 and 2,4-Di-Cl-MGV-1 Compared to the Classical TSPO Ligand PK 11195 to Counteract the Release of Chemokines from LPS-Stimulated BV-2 Microglial Cells. Biology (Basel). 2020 Sep 14;9(9). doi: 10.3390/biology9090291. PMID: 32938018; PMCID: PMC7565396.
Copy Download .nbib Format: NLM
Share it on

Biology (Basel). 2020 Sep 14;9(9). doi: 10.3390/biology9090291.

The Efficacy of the Novel TSPO Ligands 2-Cl-MGV-1 and 2,4-Di-Cl-MGV-1 Compared to the Classical TSPO Ligand PK 11195 to Counteract the Release of Chemokines from LPS-Stimulated BV-2 Microglial Cells.

Biology

Sheelu Monga, Abraham Weizman, Moshe Gavish

Affiliations

  1. Ruth and Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa 31096, Israel.
  2. Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel.
  3. Research Unit, Geha Mental Health Center and Felsenstein Medical Research Center, Petah Tikva 4910002, Israel.

PMID: 32938018 PMCID: PMC7565396 DOI: 10.3390/biology9090291

Abstract

The impact of ligands of the 18 kDa translocator protein (TSPO) on the release of chemokines is not vastly investigated. In the present study, we assessed the effect of our novel TSPO ligands 2-Cl-MGV-1 and 2,4-Di-Cl-MGV-1 compared to the classical TSPO ligand PK 11195 on chemokine release in LPS-stimulated BV-2 microglial cells. As per the effect of 2-Cl-MGV-1, CCL2, CCL3, and CCL5 were inhibited by 90%, CCL8 by 97%, and IL-2 by 77% (

Keywords: CCL; IL-2; TSPO; chemokines; inflammation; microglia

References

  1. J Neuroinflammation. 2016 Aug 31;13(1):221 - PubMed
  2. Arthritis Res Ther. 2006;8(2):R50 - PubMed
  3. Nat Immunol. 2011 Feb;12(2):167-77 - PubMed
  4. Front Neuroanat. 2015 Apr 14;9:45 - PubMed
  5. BMB Rep. 2020 Jan;53(1):20-27 - PubMed
  6. J Neuroimmunol. 1995 Jul;60(1-2):143-50 - PubMed
  7. Int J Mol Sci. 2019 Jan 30;20(3): - PubMed
  8. Exp Biol Med (Maywood). 2017 Feb;242(4):384-396 - PubMed
  9. Int J Mol Sci. 2018 Feb 05;19(2): - PubMed
  10. Cells. 2019 May 22;8(5): - PubMed
  11. Int J Mol Sci. 2018 Dec 27;20(1): - PubMed
  12. Dev Comp Immunol. 2004 May 3;28(5):443-60 - PubMed
  13. Ann Rheum Dis. 2017 May;76(5):914-922 - PubMed
  14. J Pineal Res. 2012 Apr;52(3):296-304 - PubMed
  15. Immunol Rev. 2008 Dec;226:19-28 - PubMed
  16. J Immunol. 1997 Jan 1;158(1):376-83 - PubMed
  17. Neurosci Res. 2014 Feb;79:1-12 - PubMed
  18. J Neurochem. 2009 Jan;108(1):115-25 - PubMed
  19. ALTEX. 2009;26(2):83-94 - PubMed
  20. J Interferon Cytokine Res. 2009 Jun;29(6):313-26 - PubMed
  21. Cell Death Discov. 2015 Nov 30;1:15027 - PubMed

Publication Types

Grant support